Benjamin Rengstl, MD/PhD joined BioNTech SE 2017 to develop a clinical CAR-T candidate for treatment of solid tumors. To improve CAR-T cell therapy, his team pioneered an in vivo expansion concept based on a CAR T-cell Amplifying RNA Vaccine (CARVac). A FIH clinical trial assessing BioNTech´s CLDN6-CAR in combination with CARVac is currently ongoing. As Director Immunoreceptor Therapy and Medical Expert, he is leading multiple programs to develop next generation cell- and RNA-based immunotherapies.